Patent · US Active

PD-L1 antagonist compound

US12091398B2 · kind B2 · utility

0Cited by

0References

29Claims

0Family size

Assignee

ADLAI NORTYE BIOPHARMA CO., LTD. · CN

Inventors

Pan Li · Lexington, US
Beidi XU · Zhejiang, CN
Qiaodong WEN · Hangzhou City, CN
Enguang Feng · Zhejiang, CN
Ji Wang · Amherst, US
Yang Lu · Hefei, CN
Yu Zhou · Beijing, CN
Zhiyong Yu · Zhejiang, CN
Zhiying Huang · Zhejiang, CN

Key dates

Filing date	Feb 20, 2020
Grant date	Sep 17, 2024
Priority date	—
Expiry date	Dec 7, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D471/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided is a compound represented by formula (I) and a pharmaceutical composition thereof, as well as a method for using a compound represented by formula (I) to prevent and/or treat immune-related disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.